TrialClinical and translational science2024

Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of HLX14 versus reference denosumab in healthy males: A randomized phase I study.

Nanyang Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.